Aimei Health Technology Co., Ltd.

Aimei Health Technology Co., Ltd. reported the termination of its Business Combination Agreement with United Hydrogen Group Inc. on July 7, 2026, meaning the proposed merger will not be consummated. For the second quarter ended June 30, 2026, the company recorded a net loss of $83,144, a significant decline from a net income of $424,970 in the same period last year. The company also disclosed a going concern warning due to the uncertainty of completing a business combination within the prescribed timeframe.

Aimei Health Technology Co., Ltd. announced the termination of its definitive Business Combination Agreement with United Hydrogen Group Inc. and its subsidiaries. The termination was effective July 7, 2026, meaning the proposed business combination, originally agreed upon in June 2024 and amended in June 2025, will not be completed. The company issued a press release on July 7, 2026, to announce this development.

Aimei Health Technology Co., Ltd. announced the termination of its Business Combination Agreement with United Hydrogen Group Inc., effective July 7, 2026. The agreement, originally dated June 19, 2024, was terminated because the proposed business combination was not consummated by the agreed-upon outside date. CEO Xie Junheng stated that while the transaction could not be completed within the timeframe, the company remains confident in its ability to pursue future compelling transactions.

Aimei Health Technology Co., Ltd. has extended the period to complete its initial business combination by one month, moving the termination date from July 6, 2026, to August 6, 2026. This is the twentieth such extension. To fund the required $34,330.96 extension payment, the company issued an unsecured, non-interest-bearing promissory note of the same amount to Aimei Health Ltd. The note's principal is due upon the consummation of the business combination with United Hydrogen and can be converted into private units at $10.00 per unit.

Aimei Health Technology Co., Ltd. announced that Director Julianne Huh resigned from her position effective June 24, 2026, citing personal reasons. Her resignation was accepted by the Board and was not due to any disagreement with the Company. Subsequently, on June 29, 2026, the Board approved and appointed Mr. Daniel Veikko Polvi as a new director. Mr. Polvi brings extensive experience in business management and consulting, having served as managing director of Shearwater Limited since May 2019.

Aimei Health Technology Co., Ltd. (AFJK) filed its 10-Q for the period ending March 31, 2026. The company reported a decrease in net income to $45,440 from $184,662 in the prior year's quarter, primarily due to lower interest income from its trust account. Operating costs also saw a reduction. Total assets grew slightly, while liabilities and shareholders' deficit also increased.

Aimei Health Technology Co., Ltd. has extended the termination date for its initial business combination by one month to July 6, 2026, by depositing $34,330.96 into its trust account. In connection with this extension, the company issued an unsecured promissory note of the same amount to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc. The note is interest-free and can be converted into private units prior to the business combination.

Aimei Health Technology Co., Ltd. received a notice from Nasdaq on May 19, 2026, indicating non-compliance with listing rules due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The report was due on May 15, 2026. While there is no immediate impact on the company's stock listing, failure to regain compliance could lead to delisting. The company has 60 days to file the report or submit a compliance plan and is diligently working to complete the filing.

Aimei Health Technology Co., Ltd. (AFJK) announced that it received a notice from Nasdaq on May 19, 2026, indicating non-compliance with Listing Rule 5250(c)(1). This non-compliance stems from the company's delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, which was due on May 15, 2026. While there is no immediate impact on the trading of its securities, AFJK has 60 calendar days to either file the report or submit a plan to regain compliance, with potential delisting if compliance is not restored. The company stated it is working diligently to file the report and expects to regain compliance.

Aimei Health Technology Co., Ltd. extended the period to consummate its initial business combination by one month, from May 6, 2026, to June 6, 2026. This eighteenth extension was facilitated by an aggregate $34,330.96 deposit into the trust account for public shareholders. In connection with this, the company issued an unsecured promissory note for $34,330.96 to Aimei Health Ltd and United Hydrogen Group Inc., with each contributing $17,165.48. The note does not bear interest and is convertible into private units at $10.00 per unit.